Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Kensei Yamaguchi, Satoshi Morita et al.|Cancer Medicine|2020Cited by 10
Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Kensei Yamaguchi, Satoshi Morita et al.|Cancer Medicine|2020Cited by 9
Impact of resection for ovarian metastases from colorectal cancer and clinicopathologic analysis: A multicenter retrospective study in JapanHiroyasu Kagawa, Yoichi Ajioka, Shunsuke Tsukamoto et al.|Annals of Gastroenterological Surgery|2023Cited by 8
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trialAkira Ooki, Kensei Yamaguchi, Satoshi Morita et al.|BMC Cancer|2022Cited by 7
Clinicopathological features of appendiceal goblet cell adenocarcinoma in Japan: a multicenter retrospective studyTetsuya Shiota, Kenichi Sugihara, Kohei Murata et al.|Surgery Today|2022Cited by 6